-
Part 1 | Session 6 BREAKOUT: Current Data and Future Direction in LAAC
-
Part 2 | Session 1 Session 2.1: Strategies for Calcified Coronary Lesions Anno 2022
-
Part 2 | Session 2 Session 2.2: Live Cases and Discussion
-
Part 2 | Session 4 Session 2.3: Practical Pearls Towards a More Advanced CTO Programme
-
Part 2 | Session 5 Session 2.4: Live Cases and Discussion
-
Part 2 | Session 7 BREAKOUT: Coronary Physiology in STEMI patients today: Why? When? How?
-
Part 3 | Session 1 Session 3.1 & 3.2: Keynote & Controversies
-
Part 3 | Session 2 Session 3.3: Live Cases and Discussion
-
Part 3 | Session 4 Session 3.4: Debates
-
Part 1 | Session 1 Session 1.1: Next Level Structural Heart Interventions
-
Part 1 | Session 2 Session 1.2: Live Cases and Discussion
-
Part 1 | Session 4 Session 1.3: Practical Perspectives in the Context of TAVI
Following on from the success of 2021's inaugural edition, Transcatheter Interventions Online 2022 brings together a world-class faculty to provide expert insight and educational learning on the latest developments in interventional management.
Combining expert opinion and discussion, presentations, and live cases from centres on both sides of the Atlantic, TIO 2022 delivers best-in-class learning, supporting the latest in diagnosis, treatment strategies and patient management.
Note, the live version of this session was CME accredited; this on-demand version is not.
Key Learning Objectives
- Describe the practical implications of TAVI in the context of coronary artery disease, atrioventricular valve disease and transcatheter heart valve degeneration
- Select appropriate tools for calcified coronary artery disease, including mechanical circulatory support and invasive imaging techniques
- Understand coronary physiology, novel recanalization and goal-oriented planning for chronic total occlusion
- Evaluate the role of novel oral anticoagulants in transcatheter aortic valve implantation
- Discuss the need for gender-specific trials and renal denervation
Target Audience
- Interventional Cardiologists
- Surgeons with an interest in transcatheter treatment strategies for coronary and structural heart disease
- Interventional Cardiology Nurses
More from this programme
Part 1
Day One: Structural Heart Disease
Part 2
Day Two: Coronary Heart Disease: High Risk & Complex PCI
Part 3
Day Three: Debates and Controversies
Faculty Biographies
Nicolas M Van Mieghem
Full Professor of Interventional Cardiology
Prof Van Mieghem initially intended to train as a cardiac surgeon but decided to specialise in interventional cardiology instead, following advice from a mentor. This decision was cemented when he read the first-in-human case report of transcatheter aortic valve implantation (TAVI) in Circulation by Alain Cribier in 2002. Prof Van Mieghem believes that great cardiologist genuinely cares for their patients. He names Gary Roubin, Dr Manu Malbrain and Professor Patrick Serruys among his mentors.
Academic History
Prof. Nicolas M. Van Mieghem completed his medical training at the Catholic University of Leuven (Belgium), where he earned both his medical degree and his specialist degree in cardiology. During his time in Leuven, he developed a strong interest in cardiovascular medicine, particularly in the emerging field of minimally invasive cardiac interventions. After finishing his core medical and cardiology training, he pursued multiple advanced…
Susheel Kodali
Director of the Structural Heart and Valve Center and Professor in medicine
Dr Susheel Kodali is the Director of the Structural Heart and Valve Center and a Professor in Medicine at Columbia University Medical Center. Dr Kodali attended medical school at UCLA before completing two fellowships in clinical and interventional cardiology at the UCSF Medical Centre and Columbia University Irving Medical Center.
Dr. Kodali specialises in the percutaneous treatment of coronary artery and structural heart disease, including angioplasty and TAVR. He also serves as co-investigator of the PARTNER trials and is part of the trial steering committee.
Kendra J Grubb
Surgical Director
Dr Kendra Grubb is the surgical director of the Emory Structural Heart and Valve Center. She is also an associate professor of surgery at Emory University School of Medicine.
Kendra is a champion for women's heart disease and is dedicated to improving the lives of all patients through innovation, collaboration and a patient-centred approach to the treatment of cardiovascular disease.
Her clinical interests include valve repair or replacement, coronary artery bypass graft surgery (CABG), transcatheter aortic valve replacement (TAVR) and hybrid coronary revascularization.
Dr Grubb research interests are innovative cardiac surgery technologies. She has led and participated in multiple clinical trials of innovative cardiac surgery technologies, including studies of transcatheter aortic valve replacement (TAVR), MitraClip percutaneous therapy and the GORE® conformable TAG® thoracic endoprosthesis for the primary treatment of…
Roxana Mehran
Professor of Medicine, Cardiology and Professor of Population Health Science and Policy
Roxana Mehran is an internationally recognised interventional cardiologist and clinical researcher based in New York, United States. She has spent much of her professional career at the Icahn School of Medicine at Mount Sinai and Mount Sinai Hospital, where she has become a leading figure in cardiovascular clinical trials, interventional cardiology, and outcomes research. Her work is widely noted for its focus on improving patient outcomes, advancing evidence-based care, and promoting sex-specific research in cardiovascular medicine.
Academic History
Professor Mehran pursued her medical education and postgraduate training in internal medicine and cardiology, followed by subspecialty training in interventional cardiology. Her academic career has been closely aligned with Mount Sinai, where she has advanced through senior academic ranks.
She currently holds appointments as Professor of Medicine (Cardiology) and Professor of Population Health Science…
Didier Tchétché
Didier Tchétché, (Clinique Pasteur, Toulouse, France) Graduated from the University of Paris V where Dr Tchétché obtained his post-graduate diploma of cardiovascular pathology in 2004. From 2004 to 2005, he completed a 12-month fellowship period in the Hemodynamic and Interventional Cardiology department of Clinique Pasteur in Toulouse and from 2005 to 2007 he was Head Assistant at the intensive care unit of Bichât Hospital in Paris.
In 2008, he joined the interventional cardiovascular group in Clinique Pasteur, Toulouse, and he is currently Head of the Structural programme with an experience of more than 5000 TAVI procedures. His main areas of interest are coronary interventions and valvular heart disease. He has been actively involved in many clinical trials involving new technologies and devices in the field of interventional cardiology.
David Hildick-Smith
Consultant Cardiologist
Prof David Hildick-Smith is Professor of Interventional Cardiology and Consultant Cardiologist at the Sussex Cardiac Centre - the Regional Specialist Unit. He is Director of the Cardiac Research, ex-Treasurer of the British Cardiovascular Interventions Society, and, with more than 20 years experience of Interventional Cardiology, is considered one of the country's leading experts in management of Cardiovascular complaints.
A pioneer of Interventional Cardiology, David is recognised internationally as a leader in cardiovascular diagnosis and treatment.
Lars Søndergaard
Professor Lars Søndergaard is a consultant cardiologist at Rigshospitalet – Copenhagen, Denmark. Professor of Cardiology at University of Copenhagen, he published over 300 peer reviewed articles, and more than 15 textbook chapters. His research interests are focused on adults with congenital heart diseases and catheter-based heart valve interventions, as well as congenital and structural heart diseases. He led the first-in-human transcatheter mitral valve implantation (CardiAQ) in 2012 and he actively participated to several trials, including NOTION (transcatheter vs. surgical aortic valve replacement in patients with aortic stenosis and low surgical risk), and the REDUCE randomised trial (PFO vs anti-platelet therapy after cryptogenic stroke).